After a Speedy IPO, Equillium Expands Antibody R&D to Renal Disease

Equillium, a biotech that?s looking to develop an antibody drug for immuno-inflammatory diseases, has added a form of renal disease to the indications for which it aims to develop medicines. It?s the latest step in a fast-moving journey for the La Jolla, CA-based company, which raised about $65 million in an initial public offering in [?]